BP1蛋白在三阴性乳腺癌组织中的表达及意义

Expression of BP1 protein and its significance in triple negative breast cancer

目的检测betaprotein-1（BP1）蛋白在三阴性乳腺癌组织中的表达及意义。方法采用免疫组化S-P法检测36例三阴性乳腺癌及癌旁组织中BP1蛋白的表达，分析其与三阴性乳腺癌临床病理因素和雄激素受体的关系。结果BP1蛋白在三阴性乳腺癌及其癌旁组织中阳性率分别为72．2％、2．8％，有显著性差异（P〈0．005）。雄激素受体（＋）乳腺癌组织中BP1阳性表达率为36．4％（4／11），雄激素受体（-）乳腺癌组织中为92．0％（23／25），两者有统计学差异（P〈0．05）。BP1在I、Ⅱ、Ⅲ期乳腺癌中阳性表达率分别：50．0％（3／6）、62．5％（10／16）、100．0％（14／14），三者间比较差异有统计学意义（P〈0．025）。浸润性导管癌的三阴性乳腺癌组织中BP1的表达率86．2％（25／29），而其他类型表达率28．6％（2／7），经比较差异有统计学意义（P〈0．025）。BP1与肿瘤大小和淋巴结转移无显著差异（P〉0．05，P〉0．50）。结论BP1蛋白在三阴性乳腺癌中高表达，有望成为治疗三阴性乳腺癌的新靶点，联合BP1和雄激素受体表达可更好的指导三阴性乳腺癌患者临床治疗及判断预后。

Objective To investigate expression of BPlprotein in triple negative breast cancer （TNBC）tissues and its significance. Methods Immunohistochemical methods were used to detect expression of BP1 protein in cancer tissues and cancer-surrounding tissues of 36 women with TNBC, and to explore correlations between expression of TNBC and clinopathological factors of TNBC and androgen receptor （AR）. Results The positive expression rates of BPlpretein in triple negative breast cancer and surrounding tissues were 72.2% and 2.8% respectively, and the difference was statistically significant （P 〈 0. 005 ）. The positive expression rate of BP1 in AR positive TNBC was 36.4 % （4/11 cases ） and that in AR negative TNBC was 92% （23/25） ,there was a significant difference between them （ P 〈0. 050） . The positive expression rates of BP1 in stages I, II and III TNBC were 62.5 % （ 10/16）, 100 % （14/14） and 50 % （3/6） respectively, there was a significant difference among the three groups （P 〈 0. 025）. The positive expression rates of BPlprotein in infiltrating duct carcinoma of TNBC was 86.2% （25/29）, and that was 28.6% （2/7） in other types of TNBC , there was a significant difference between them （both P 〈 0.025）. Nevertheless, no correlations were found between expression of BP1 and tumor size, lymphatic metastasis of the tumor（both P 〉 0.05）. Conclusion High expression of BP1 in TNBC may make it become a new therapeutic target of TNBC, and combined detection of expressions of BP1 and AR in TNBC tissues guides clinical treatment and predicts prognosis of TNBC better.